A detailed history of Cwm, LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Cwm, LLC holds 56 shares of CRNX stock, worth $3,064. This represents 0.0% of its overall portfolio holdings.

Number of Shares
56
Previous 11 409.09%
Holding current value
$3,064
Previous $0 Infinity%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 08, 2024

BUY
$43.83 - $54.98 $1,972 - $2,474
45 Added 409.09%
56 $3,000
Q2 2024

Jul 09, 2024

BUY
$42.12 - $51.91 $463 - $571
11 New
11 $0
Q3 2023

Oct 11, 2023

SELL
$15.97 - $30.59 $287 - $550
-18 Reduced 23.08%
60 $2,000
Q2 2023

Aug 03, 2023

BUY
$15.73 - $23.6 $1,226 - $1,840
78 New
78 $1,000
Q1 2022

Apr 21, 2022

SELL
$17.15 - $28.31 $377 - $622
-22 Closed
0 $0
Q4 2021

Jan 31, 2022

BUY
$19.35 - $28.41 $425 - $625
22 New
22 $1,000

Others Institutions Holding CRNX

About Crinetics Pharmaceuticals, Inc.


  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $2.94B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Cwm, LLC Portfolio

Follow Cwm, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.